http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005115393-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f312787490f5213c1e8acdcdba492f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cce9b8198f2c9cf42e537467dfcd9f22
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
filingDate 2005-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ade5cb610b0b7d5c8d3648e134690e93
publicationDate 2005-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2005115393-A1
titleOfInvention An anti-hyperlipemia composition
abstract The present invention offers an anti-hyperlipemia composition, containing Acipimox and Pitavastatin, or their salts, esters and solvates. The proportion by weight is (50-800): 1, preferably (100-400): 1, more preferably 200:1. Acipimox can be used in combination with Pitavastatin in synergistic action, the effect of anti-hyperlipemia is better than the combination of Acipimox and L ovastatin.
priorityDate 2004-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID132804
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5310993
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395564
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226432772
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5282452
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID245003257
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127744388

Total number of triples: 23.